Idiopathic pulmonary fibrosis

A case discussion

Meghan K. Felton, Brian Bautista, Lee E. Morrow, Mark A. Malesker

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The purpose of this report is to describe the case of a 68-year-old man who was treated for idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease that is characterized by progressive deterioration of pulmonary function. He was initially prescribed pirfenidone and developed significant gastric distress. The treatment was transitioned to nintedanib. This article will provide the pharmacist with a therapeutic overview of IPF, as well as review the unique process involved with drug acquisition, dosing, patient education, and monitoring of pirfenidone and nintedanib. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: Pirfenidone and nintedanib are the only medications in the United States approved to treat IPF. These treatments have distinctive properties that differ from past therapies for IPF. CONCLUSION: It is important for pharmacists to understand the treatment recommendations for IPF and to review the process for acquisition, dosing, and administration of pirfenidone and nintedanib to better assist physicians and patients and improve therapeutic outcomes.

Original languageEnglish (US)
Pages (from-to)406-411
Number of pages6
JournalConsultant Pharmacist
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Idiopathic Pulmonary Fibrosis
Pharmacists
Therapeutics
Pharmacies
Physiologic Monitoring
Patient Education
Consultants
Lung Diseases
Stomach
Nursing
Physicians
Lung
pirfenidone
nintedanib
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Idiopathic pulmonary fibrosis : A case discussion. / Felton, Meghan K.; Bautista, Brian; Morrow, Lee E.; Malesker, Mark A.

In: Consultant Pharmacist, Vol. 32, No. 7, 01.07.2017, p. 406-411.

Research output: Contribution to journalArticle

Felton, Meghan K. ; Bautista, Brian ; Morrow, Lee E. ; Malesker, Mark A. / Idiopathic pulmonary fibrosis : A case discussion. In: Consultant Pharmacist. 2017 ; Vol. 32, No. 7. pp. 406-411.
@article{0eb1c421730e40f1b7930eb5be61fe2c,
title = "Idiopathic pulmonary fibrosis: A case discussion",
abstract = "OBJECTIVE: The purpose of this report is to describe the case of a 68-year-old man who was treated for idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease that is characterized by progressive deterioration of pulmonary function. He was initially prescribed pirfenidone and developed significant gastric distress. The treatment was transitioned to nintedanib. This article will provide the pharmacist with a therapeutic overview of IPF, as well as review the unique process involved with drug acquisition, dosing, patient education, and monitoring of pirfenidone and nintedanib. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: Pirfenidone and nintedanib are the only medications in the United States approved to treat IPF. These treatments have distinctive properties that differ from past therapies for IPF. CONCLUSION: It is important for pharmacists to understand the treatment recommendations for IPF and to review the process for acquisition, dosing, and administration of pirfenidone and nintedanib to better assist physicians and patients and improve therapeutic outcomes.",
author = "Felton, {Meghan K.} and Brian Bautista and Morrow, {Lee E.} and Malesker, {Mark A.}",
year = "2017",
month = "7",
day = "1",
doi = "10.4140/TCP.n.2017.406",
language = "English (US)",
volume = "32",
pages = "406--411",
journal = "The Senior care pharmacist",
issn = "2639-9636",
publisher = "American Society of Consultant Pharmacists",
number = "7",

}

TY - JOUR

T1 - Idiopathic pulmonary fibrosis

T2 - A case discussion

AU - Felton, Meghan K.

AU - Bautista, Brian

AU - Morrow, Lee E.

AU - Malesker, Mark A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - OBJECTIVE: The purpose of this report is to describe the case of a 68-year-old man who was treated for idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease that is characterized by progressive deterioration of pulmonary function. He was initially prescribed pirfenidone and developed significant gastric distress. The treatment was transitioned to nintedanib. This article will provide the pharmacist with a therapeutic overview of IPF, as well as review the unique process involved with drug acquisition, dosing, patient education, and monitoring of pirfenidone and nintedanib. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: Pirfenidone and nintedanib are the only medications in the United States approved to treat IPF. These treatments have distinctive properties that differ from past therapies for IPF. CONCLUSION: It is important for pharmacists to understand the treatment recommendations for IPF and to review the process for acquisition, dosing, and administration of pirfenidone and nintedanib to better assist physicians and patients and improve therapeutic outcomes.

AB - OBJECTIVE: The purpose of this report is to describe the case of a 68-year-old man who was treated for idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease that is characterized by progressive deterioration of pulmonary function. He was initially prescribed pirfenidone and developed significant gastric distress. The treatment was transitioned to nintedanib. This article will provide the pharmacist with a therapeutic overview of IPF, as well as review the unique process involved with drug acquisition, dosing, patient education, and monitoring of pirfenidone and nintedanib. SETTINGS: Community pharmacy, nursing facility pharmacy, consultant pharmacy practice. PRACTICE CONSIDERATIONS: Pirfenidone and nintedanib are the only medications in the United States approved to treat IPF. These treatments have distinctive properties that differ from past therapies for IPF. CONCLUSION: It is important for pharmacists to understand the treatment recommendations for IPF and to review the process for acquisition, dosing, and administration of pirfenidone and nintedanib to better assist physicians and patients and improve therapeutic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85023205264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023205264&partnerID=8YFLogxK

U2 - 10.4140/TCP.n.2017.406

DO - 10.4140/TCP.n.2017.406

M3 - Article

VL - 32

SP - 406

EP - 411

JO - The Senior care pharmacist

JF - The Senior care pharmacist

SN - 2639-9636

IS - 7

ER -